Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-438162, MEK inhibitor · 2 trials · 4 indications
The ACR (American College of Rheumatology) Criteria is a standard criteria to measure the effectiveness of various arthritis medications or treatments in clinical trials for Rheumatoid Arthritis. The ACR 20 has a positive outcome if 20% improvement in tender or swollen joint counts were achieved as well as a 20% improvement in at least three of the other five criteria.
| Arm | Type | Description |
|---|---|---|
| ARRY-438162 (Schedule 1) | EXPERIMENTAL | - |
| ARRY-438162 (Schedule 2) | EXPERIMENTAL | - |
| ARRY-438162 (Schedule 3) | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| ARRY-438162 (MEK 162) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARRY-438162, MEK inhibitor; oral | DRUG | multiple dose, single schedule |
| Placebo; oral | DRUG | matching placebo |
| ARRY-438162 (MEK162), MEK inhibitor; oral | DRUG | Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule. |
Key Inclusion Criteria: * Diagnosis of rheumatoid arthritis, based on the American College of Rheumatology (ACR) 1987 Revised Criteria, prior to first dose of study drug. * Patient has received a stable dose of methotrexate for ≥ 6 weeks prior to first dose of study drug and is willing to continue ...
Top 20 of 26 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Adalimumab, Upadacitinib, Lutikizumab, Ravagalimab |
| Bristol-Myers Squibb Company | BMY | 6 | PHASE3 | Abatacept, Zolacabtagene autoleucel, BMS-986528, BMS-986454 |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Baricitinib, LY4213663, LY4298445 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Guselkumab |
| AstraZeneca PLC | AZN | 4 | PHASE2 | AZD1163, AZD0120, AZD5492, Surovatamig |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | Ianalumab, PIT565, Secukinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE2 | Tulisokibart, MK-1045 |
| AnaptysBio, Inc. | ANAB | 1 | PHASE2 | Rosnilimab |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY002-072 |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Sarilumab, SAR448501 |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| XBiotech, Inc. | XBIT | 1 | PHASE2 | Natrunix |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE2 | AB-101 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | GS-0151 |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
| Xencor, Inc. | XNCR | 1 | PHASE1 | Plamotamab |
| Adicet Bio Inc | ACET | 1 | PHASE1 | ADI-001 |
| Pfizer Inc. | PFE | 2 | - | tofacitinib |
| Jade Biosciences, Inc. | JBIO | 1 | PHASE1 | JADE201 |
ARRY-438162 is an investigational oral small molecule that has been studied in advanced solid tumors, including advanced or metastatic biliary cancer and metastatic colorectal cancer, and in rheumatoid arthritis. It is not approved for any indication and remains in clinical development.
ARRY-438162 is a MEK inhibitor. It targets MEK, a kinase in the MAPK signaling pathway that transmits growth signals from RAS and RAF to ERK. By inhibiting MEK, the drug is designed to interrupt this signaling cascade in tumor cells.
Pfizer, Inc. (ticker PFE) is the developer of ARRY-438162. The compound was originally discovered by Array BioPharma and later advanced by Pfizer, which holds the development program for this MEK inhibitor.
ARRY-438162 is in Phase 1 development overall. A Phase 1 trial in advanced cancer has been completed, and a separate Phase 2 study in rheumatoid arthritis has also been completed. The drug is investigational and has not been approved by the FDA.
ARRY-438162 has been evaluated in two completed trials: NCT00959127, a Phase 1 study in patients with advanced cancer that enrolled 93 participants in the United States, and NCT00650767, a Phase 2 study in rheumatoid arthritis that enrolled 201 participants across the United States, Argentina, Brazil, Hungary, Peru, Poland, and Romania.
Yes. ARRY-438162 is also known as MEK162. Both names refer to the same oral small molecule MEK inhibitor developed by Pfizer. The compound is sometimes described simply as a MEK inhibitor in study titles and publications.